Valneva is a French specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need. The company has been listed on Euronext Paris since 2007 and on Nasdaq since 2021

The Company has leveraged its expertise and capabilities both to successfully commercialize two vaccines and to rapidly advance a broad range of vaccine candidates into and through the clinic, including candidates against Lyme disease, the chikungunya virus and COVID-19

Valneva announced positive Phase 3 results of its VLA2001 COVID-19 vaccine, meeting both co-primary endpoints demonstrating superior neutralizing antibody titer levels as well as better tolerability profile compared to active comparator AstraZeneca’s approved Vaxzevria vaccine. On the back of these results, Valneva has commenced rolling submission for initial approval in both the UK and Europe

Proceeds will be mainly used to fund the development of the Lyme VLA15 vaccine candidate through completion of Phase 2, the chikungunya VLA1553 vaccine candidate through BLA approval, the COVID-19 VLA2001 vaccine candidate through conditional licensure, and for working capital and general corporate purposes